EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genetic Analysis of Melanoma Types Using Japanese Genomic Database

Hayato Matsumoto iD, Hiromi Nagano iD, Takayuki Kyutoku, Masaru Yamashita

The Laryngoscope · 2024

DOI: 10.1002/lary.31676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2024. Verfasst von Hayato Matsumoto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. Hauptthemen laut MEDLINE: Melanoma, Mutation, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The purpose of this study is to compare genetic mutations, tumor mutation burden (TMB), and the effects of molecular targeted drugs and immune checkpoint inhibitors (ICIs) in head and neck mucosal melanoma (HNMUM) with those in skin melanoma (SKM) and ocular melanoma (OM).

Methods

Data were analyzed for 72 consecutive patients with HNMUM, including 366 with SKM and 31 with OM, registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) between June 2019 and October 2023. Genetic alterations and TMB were determined by FoundationOne CDx next‐generation sequencing.

Results

The top 10 mutations in HNMUM were RAD21 (47.2%), NBN (45.8%), MYC (40.3%), LYN (31.9%), NRAS (29.1%), IRF4 (23.6%), DAXX (22.2%), KIT (22.2%), NOTCH3 (20.8%), and DDR1 (19.4%), with 16.6 ± 0.8 (mean ± SEM) mutations/individual. In SKM, BRAF ( p = 0.04) mutation was associated with a significantly better prognosis. The TMB values were 5.7 ± 2.1 (mean ± SEM) in HNMUM, 4.1 ± 0.2 in SKM, and 3.4 ± 0.9 in OM, with no significant differences among the three groups. The median survival time for patients with distant metastases was 803 (95% confidence interval: 539‐NA) days for HNMUM, 1413 (831–2172) days for SKM, and 1138 (438‐NA) days for OM.

Conclusions

The top 10 mutations in HNMUM are closer to those in OM than those in SKM. There was no significant difference in TMB values or survival rates with regard to the therapeutic effect of ICIs among the diseases, which suggests that current treatment of HNMUM with ICIs is appropriate. Level of Evidence 3 Laryngoscope , 2024

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaMutationSkin NeoplasmsHumansMaleJapanFemaleMiddle AgedAgedDatabases, GeneticAdultHead and Neck NeoplasmsImmune Checkpoint InhibitorsGenetic TestingHigh-Throughput Nucleotide SequencingAged, 80 and overMolecular Targeted TherapyEast Asian People

Stichwörter der Autor:innen

genetic mutationshead and neck mucosal melanomaocular melanomaskin melanomatumor mutation burden

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Otolaryngology Head and Neck Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

ORCID-Profile: Hayato Matsumoto, Hiromi Nagano

Zitieren

APA

Matsumoto, H., Nagano, H., Kyutoku, T., & Yamashita, M. (2024). Genetic Analysis of Melanoma Types Using Japanese Genomic Database. The Laryngoscope. https://doi.org/10.1002/lary.31676

Vancouver

Matsumoto H, Nagano H, Kyutoku T, Yamashita M. Genetic Analysis of Melanoma Types Using Japanese Genomic Database. The Laryngoscope. 2024. doi:10.1002/lary.31676

BibTeX
@article{Matsumoto2024,
  author = {Matsumoto, Hayato and Nagano, Hiromi and Kyutoku, Takayuki and Yamashita, Masaru},
  title = {Genetic Analysis of Melanoma Types Using Japanese Genomic Database},
  journal = {The Laryngoscope},
  year = {2024},
  doi = {10.1002/lary.31676}
}
Kostenlos starten →